About AGCP Farmacêuticos LDA
Our Company
Who We Are
AGCP Farmacêuticos LDA is a vertically integrated company — a future leader in the pharmaceutical industry. With state-of-the-art facilities in Portugal, we are focused on producing the highest quality pharmaceutical-grade natural medicines and plant extract-based therapeutics.
Through our revolutionary manufacturing methods, we achieve extremely high production output with a fraction of the cost and land footprint required by conventional approaches.
We develop, manufacture, and supply the highest quality oil-soluble and nature-derived products, while heavily targeting research and development for the purpose of creating new proprietary formulations, drug delivery systems, and specialty research studies with leading universities around the world.
Our Platform
Our Advanced Drug Delivery Platform
Our platform operates at the cellular membrane level, combining water-soluble and oil-soluble ingredients within a single formulation. Our prime active ingredients are natural and widely available.
By combining active pharmaceutical ingredients with specific hormones or proteins, we utilize natural molecular exchange mechanisms and the principles of human cell biology. Our formulations are also designed to deliver essential microelements and supplements to support optimized biochemical functions.
AGCP's research focuses on stable and potent small-molecule-loaded formulations. We leverage AI algorithms that analyze extensive experimental data to identify disease-associated targets and predict their interactions with potential drug candidates — enabling a more efficient and targeted approach to drug discovery while reducing development costs.
Our People
Leadership Team
Lawrence Fine
Chief Executive Officer
Chairman of the Board and CEO of AGCP, Lawrence brings extensive M&A and commercialization experience spanning Fortune 500 companies, with deep expertise in Technology, Healthcare, and Biotechnology. He has a proven track record in divestments, acquisitions, and strategic growth — and holds a PhD in Engineering from Stanford University and an MBA from Emory University.
Dr. Alexander Dementev
President & Chief Technology Officer
An experienced formulation and materials scientist with over thirty years in pharmaceutical and natural health product development. Alexander specializes in nanotechnology, novel drug synthesis, HPLC method development, and pharmaceutical due diligence. Notable achievement: oil-in-water nano-suspensions with average particle size below 10nm and stability exceeding eighteen months. Holds a Master’s in Applied Physics and a PhD in Analytical Chemistry.
EU Licensed Producer
European pharmaceutical producer license
Sub-10nm Particles
Proven nanoemulsion stability exceeding 4 years
AI-Driven R&D
Machine learning-assisted drug candidate optimization